Leading global law firm Herbert Smith Freehills has advised ICBC International Capital Limited as the sole sponsor of the IPO and listing of TOT BIOPHARM International Company Limited on the Stock Exchange of Hong Kong.
The IPO raised over HK$500 million, with the listing on 8 November 2019.
TOT BIOPHARM is a China-based clinical-stage biopharmaceutical company dedicated to developing and commercialising innovative oncology drugs and therapies.
"There has been a real uptick of Hong Kong IPOs in recent weeks and we are delighted to have advised ICBCI on TOT BIOPHARM's Chapter 18A listing," said partner Matt Emsley.
Matt led the team advising ICBCI assisted by senior associate George Wu and associates Jamie Fong, Afra Li and Kris Cheung. Additional support provided by Singapore partner Siddhartha Sivaramakrishnan and associate Sophia Tan.